Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 49

Results For "stent"

930 News Found

Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as CEO
People | September 20, 2024

Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as CEO

She brings an overall Techno Commercial experience of 22+ Years in various Organizations


Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis
Drug Approval | September 19, 2024

Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids


Piramal Pharma's GHG Commitment Validated and Approved by SBTi
Sustainability | September 17, 2024

Piramal Pharma's GHG Commitment Validated and Approved by SBTi

This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'


FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L) cancer immunotherapy
Drug Approval | September 16, 2024

FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L) cancer immunotherapy

Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous


Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC
Clinical Trials | September 16, 2024

Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC

KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival


Merck announces positive top-line results from Phase 3 trial evaluating efficacy and safety of Gardsil 9
Clinical Trials | September 11, 2024

Merck announces positive top-line results from Phase 3 trial evaluating efficacy and safety of Gardsil 9

The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9


Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial
Clinical Trials | September 10, 2024

Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial

TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population


Suspected Mpox case under investigation
News | September 09, 2024

Suspected Mpox case under investigation

The patient has been isolated in a designated hospital and is currently stable


Strides receive USFDA approval for Theophylline ER tablets, 300 mg and 450 mg
Drug Approval | September 06, 2024

Strides receive USFDA approval for Theophylline ER tablets, 300 mg and 450 mg

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug


Akums appoints Shantanu R Chobhe as Corporate Quality Assurance Head
People | September 05, 2024

Akums appoints Shantanu R Chobhe as Corporate Quality Assurance Head

Chobhe brings over 30 years of extensive experience in quality and regulatory management within the pharmaceutical industry